Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

and hip in more than 50 countries, including the European Union, Canada and Latin America.

In the US, this medicine is under review by the Food and Drug Administration (FDA) for relief of the signs and symptoms of osteoarthritis.

"Evidence from the large-scale TARGET study has shown that Prexige is associated with significantly smaller increases in blood pressure than commonly used NSAIDs," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "The new research underlines how important it is for osteoarthritis patients to have a treatment option such as Prexige."

The study presented at EULAR was a four-week, multicenter, randomized, double-blind, double-dummy, parallel group trial of 787 hypertensive osteoarthritis patients age 50 or older with ambulatory blood pressure of 140/90 mmHg or below, who were being treated with a antihypertensive medicine. A total of 741 patients completed the study, which compared Prexige 100 mg once-daily with ibuprofen 600 mg taken three times daily.

At the end of the study, patients on Prexige showed a decrease in mean ambulatory systolic blood pressure of 2.7 mmHg compared to a 2.2 mmHg increase in patients taking ibuprofen, giving an estimated difference of 5.0 mmHg between the groups (p<0.001). Mean ambulatory diastolic blood pressure decreased by 1.5 mmHg in Prexige patients compared to a 0.5 mmHg increase in those on ibuprofen, an estimated difference of 2.0 mmHg (p<0.001).

Systolic pressure represents the pressure within blood vessels when the heart contracts, while diastolic pressure is measured when the heart is at rest between beats. Both are monitored while the patient is active (or ambulatory), considered to be the most rigorous way of studying blood pressure. They are measured in millimeters of mercury or mmHg.

Results further showed Prexige and ibuprofen had similar efficacy as well as a comparable incidence of adverse events. These were mostly mild and did no
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:6/2/2015)... 2015 Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend of twelve cents per outstanding share, ... at the close of business on June 12, 2015. ... in 1906, Kewaunee Scientific Corporation is a recognized global ... healthcare, and technical furniture products. Products include steel, wood, ...
(Date:6/2/2015)... REPORT HIGHLIGHTS The global market for ... This market is expected to increase from more than $4.1 ... compound annual growth rate (CAGR) of 13.6% over the five-year ... An in-depth analysis of the global markets and ... from 2013, estimates for 2014, and projections of compounds annual ...
(Date:6/2/2015)... , June 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Drug ... Markets and Companies" to their offering. ... system (CNS) is a challenge in the treatment ... into the CNS or administered systematically (e.g., by ...
Breaking Medicine Technology:Global Markets and Technologies for Medical Lasers 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3
... Genmab A/S (OMX:,GEN) announced today a Phase ... of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA),patients, stable ... which,will consist of two parts and include approximately ... addition of a subcutaneous method of administrating ofatumumab ...
... and benefits of early treatment ... with liraglutide versus glimepiride, SAN FRANCISCO, June ... the American Diabetes Association (ADA),demonstrated that once-daily liraglutide when taken ... with type 2 diabetes, as compared to glimepiride, a widely ...
Cached Medicine Technology:Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study 2Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study 3Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 2Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 3Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 4
(Date:6/3/2015)... Veatch Consulting Services is excited to announce their ... business in April 2006, they have made it a ... Each and every year they have worked diligently in ... say that they are off to a great start ... this year is the Customer Review site veatchconsultingreviews.weebly.com. At ...
(Date:6/3/2015)... Israel (PRWEB) June 03, 2015 ... emergency mass-notification, multi-channel solutions, reported of its "behind-the-scenes" ... the past few months. Since March this year, ... has been inflicting the South-American country, putting millions ... ash and gas into the atmosphere. "evigilo's technology, ...
(Date:6/2/2015)... (PRWEB) June 03, 2015 BALTIMORE, Md. ... to write a book about wellness after being diagnosed ... she believes that through lifestyle changes which enhance health, ... In “ A Wellspring for Wellness ,” she ... diseases. , This book provides an overview of ...
(Date:6/2/2015)... The organic cotton market is again growing according ... conducted by Textile Exchange, an international nonprofit organization committed ... today, encompasses extensive data about organic cotton from seed ... takes the opportunity to celebrate those who are building ... last several years have been complicated for the organic ...
(Date:6/2/2015)... Kan. (PRWEB) June 02, 2015 Concorde ... Bell as President and COO. Bell will manage day-to-day ... , “I’m looking forward to the opportunity to help ... students,” Bell said. “I joined Concorde in part due ... Institute that highlighted Concorde colleges in Memphis and Portland.” ...
Breaking Medicine News(10 mins):Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:Thousands of Lives Saved, Millions Protected in Chile 2Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 2Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 4Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 5Health News:Concorde Career Colleges Announces New President and COO 2
... poultry made its way to the food chain via the ... strain// of bird flu in early February this year. ... almost 850 tons of turkey had to pass through the ... the interim period between outbreak of the avian influenza and ...
... Haikerwal, today urged more Australians to donate blood and donate ... ,Dr Haikerwal said the AMA strongly supports the ... designed to raise the number of Australian blood donors and ... year. ,“Blood donors save lives,” Dr Haikerwal ...
... are varied reactions to the U.S panel hearing ... , The Senate Health, Education, Labor and ... Food and Drug Administration legal authority to approve alternative ... Yet it has drawn both brickbats and ...
... article published in the prestigious international journal 'The Lancet' by ... Darwin// has revealed a breakthrough in the battle to treat ... the worlds population. ,There are two major strains ... attention focuses on the more virulent P. falciparum, vivax malaria ...
... in a duck farm in Chonan, in central South Korea. ... bird flu on Thursday//. The cause was identified as "highly ... bird flu outbreak since November reported in South Korea. H5N1 ... Korea. ,The culling of over 55,000 poultry will ...
... According to statistics over one lac people Indians are diagnosed ... die as they do not get timely treatment. ... Check-up package in connection with World Kidney Day-2007. The camp ... and urine analysis for random glucose and creatinine. ...
Cached Medicine News:Health News:Generic Biologics – U.S Panel Hearing Draws Mixed Response 2Health News:Researchers Discover Breakthrough in Malaria Treatment 2
... manual autoclaves set the standard for steam ... to compliment any healthcare and laboratory facility. ... of your sterilization needs. Time tested reliability ... product. The Tuttnauer M Series is also ...
Subjective refraction unit, computer controlled and programmable. Two versions: with and without prisms....
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
Non-sterile oncoseed seeds consists of a welded titanium capsule containing....
Medicine Products: